πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 96 of 173

  1. US 9044514

    Lipid-peptide-polymer conjugates and nanoparticles thereof

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9046529

    Prostatitis-associated antigens and methods of use thereof

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9045742

    Recombinant Edwardsiella bacterium

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9045752

    NKX3-1 saRNA and KLF4 saRNA and uses thereof

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9045526

    Compound and method for modulating opioid receptor activity

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9045474

    Compounds and compositions for mitigating tissue damage and lethality

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9045416

    WNT protein signalling inhibitors

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9045401

    Methods for treating or ameliorating a melanoma and killing melanoma cells

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9044518

    Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9044611

    Systems and methods for selectively migrating cells using electric fields

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9045731

    Compositions and methods for improving the functional efficacy of stem cell-derived cardiomyocytes

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9044391

    Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9045559

    Method for screening inhibitors of interleukin-32 (IL-32)

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9040059

    Recombinant bacterium capable of eliciting a protective immune response against C. perfringens

    Expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9040626

    Nanofibers and morphology shifting micelles

    Expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9040567

    BAX agonist, compositions, and methods related thereto

    Expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9040241

    Genetic markers of mental illness

    Expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9040157

    Hollow nanoparticles and nanocomposites and methods of making hollow nanoparticles and nanocomposites

    Expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9034903

    Acyl piperidine inhibitors of soluble epoxide hydrolase

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9034642

    Genes of an otitis media isolate of nontypeable Haemophilus influenzae

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9034336

    Immunomodulators and immunomodulator conjugates

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9037214

    Multi-modality nanoparticles having optically responsive shape

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9034318

    Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9029321

    Methods and compositions for targeting adipose cells in mammals

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9029557

    Labeled A4B2 ligands and methods therefor

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9029521

    EML4-ALK fusion gene

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9028499

    Bone cutting device

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9029342

    Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9029550

    Conformationally restricted urea inhibitors of soluble epoxide hydrolase

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9029502

    Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9029509

    Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR)

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9023340

    Wnt inhibitors for human stem cell differentiation

    Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9023984

    Diagnostic and therapeutic target for autoimmune diseases and uses thereof

    Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9023798

    Cystinosin replacement factor

    Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9023356

    Treatment method using EGFR antibodies and SRC inhibitors and related formulations

    Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9023823

    Micro-RNA's that regulate muscle cells

    Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9018380

    Heterocyclic modulators of HIF activity for treatment of disease

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9017644

    Methods of treating autoimmune disorders and/or inflammatory disorders

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9017730

    Compositions and uses of materials with high antimicrobial activity and low toxicity

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9017653

    Nitric oxide-releasing compositions and methods

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9018367

    Single stranded DNA aptamers binding NF-ΞΊB/RelA

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9018210

    Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9017661

    Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9012455

    Pharmaceutical compositions containing an indoyl isoquinoline containing compound and uses thereof

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9012134

    CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9012407

    Therapies which act on neuropeptide S receptors

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9011844

    Human cystathionine Ξ²-synthase variants and methods of production thereof

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9011857

    Methods of treating cancer by administering EMP2 antibodies

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.